BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26186253)

  • 1. Her-2 Expression in Gastroesophageal Intestinal Metaplasia, Dysplasia, and Adenocarcinoma.
    Almhanna K; Rosa M; Henderson-Jackson E; Jiang K; Shamekh R; Sayegh Z; Malafa MP; Coppola D
    Appl Immunohistochem Mol Morphol; 2016 Oct; 24(9):633-638. PubMed ID: 26186253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
    Walch A; Specht K; Bink K; Zitzelsberger H; Braselmann H; Bauer M; Aubele M; Stein H; Siewert JR; Höfler H; Werner M
    Lab Invest; 2001 Jun; 81(6):791-801. PubMed ID: 11406641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of cyclin B1 in the metaplasia-dysplasia-carcinoma sequence of Barrett esophagus.
    Geddert H; Heep HJ; Gabbert HE; Sarbia M
    Cancer; 2002 Jan; 94(1):212-8. PubMed ID: 11815979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction.
    Ecker BL; Taylor L; Zhang PJ; Furth EE; Ginsberg GG; McMillan MT; Datta J; Czerniecki BJ; Roses RE
    PLoS One; 2016; 11(8):e0161781. PubMed ID: 27559738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oncogene amplification and genetic heterogeneity in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett esophagus].
    Walch A; Bink K; Hutzler P; Zitzelsberger H; Braselmann H; Aubele M; Höfler H; Werner M
    Verh Dtsch Ges Pathol; 2001; 85():257-63. PubMed ID: 11894407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early HER2 dysregulation in gastric and oesophageal carcinogenesis.
    Fassan M; Mastracci L; Grillo F; Zagonel V; Bruno S; Battaglia G; Pitto F; Nitti D; Celiento T; Zaninotto G; Fiocca R; Rugge M
    Histopathology; 2012 Nov; 61(5):769-76. PubMed ID: 22882541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus.
    Srivastava A; Hornick JL; Li X; Blount PL; Sanchez CA; Cowan DS; Ayub K; Maley CC; Reid BJ; Odze RD
    Am J Gastroenterol; 2007 Mar; 102(3):483-93; quiz 694. PubMed ID: 17338734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allelic loss involving the tumor suppressor genes APC and MCC and expression of the APC protein in the development of dysplasia and carcinoma in Barrett esophagus.
    Bektas N; Donner A; Wirtz C; Heep H; Gabbert HE; Sarbia M
    Am J Clin Pathol; 2000 Dec; 114(6):890-5. PubMed ID: 11338478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions.
    Geddert H; Zeriouh M; Wolter M; Heise JW; Gabbert HE; Sarbia M
    Am J Clin Pathol; 2002 Jul; 118(1):60-6. PubMed ID: 12109857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anterior gradient 2 profiling in Barrett columnar epithelia and adenocarcinoma.
    Pizzi M; Fassan M; Realdon S; Balistreri M; Battaglia G; Giacometti C; Zaninotto G; Zagonel V; De Boni M; Rugge M
    Hum Pathol; 2012 Nov; 43(11):1839-44. PubMed ID: 22521076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the high mobility group proteins HMGI(Y) correlates with malignant progression in Barrett's metaplasia.
    Chen X; Lechago J; Ertan A; Ergun G; Verm R; Bridges M; Johnson C; Woods K; Meriano F; Chirala M; Younes M
    Cancer Epidemiol Biomarkers Prev; 2004 Jan; 13(1):30-3. PubMed ID: 14744729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological assessment & use of immunohistochemical markers for detection of dysplasia in Barrett's esophageal mucosa.
    Kinra P; Gahlot GPS; Yadav R; Baloda V; Makharia GK; Gupta SD; Das P
    Pathol Res Pract; 2018 Jul; 214(7):993-999. PubMed ID: 29764708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes after liquid nitrogen spray cryotherapy in Barrett's esophagus-associated high-grade dysplasia and intramucosal adenocarcinoma: 5-year follow-up.
    Ramay FH; Cui Q; Greenwald BD
    Gastrointest Endosc; 2017 Oct; 86(4):626-632. PubMed ID: 28235596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acidic fibroblast growth factor is progressively increased in the development of oesophageal glandular dysplasia and adenocarcinoma.
    Soslow RA; Nabeya Y; Ying L; Blundell M; Altorki NK
    Histopathology; 1999 Jul; 35(1):31-7. PubMed ID: 10383711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.
    Wani S; Falk GW; Post J; Yerian L; Hall M; Wang A; Gupta N; Gaddam S; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Goldblum J; Lieberman DA; Sampliner RE; Sharma P
    Gastroenterology; 2011 Oct; 141(4):1179-86, 1186.e1. PubMed ID: 21723218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
    Morris CD; Armstrong GR; Bigley G; Green H; Attwood SE
    Am J Gastroenterol; 2001 Apr; 96(4):990-6. PubMed ID: 11316217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.
    Hanas JS; Lerner MR; Lightfoot SA; Raczkowski C; Kastens DJ; Brackett DJ; Postier RG
    Cancer; 1999 Sep; 86(5):756-63. PubMed ID: 10463972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
    Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
    Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus.
    van Dekken H; Hop WC; Tilanus HW; Haringsma J; van der Valk H; Wink JC; Vissers KJ
    Am J Clin Pathol; 2008 Nov; 130(5):745-53. PubMed ID: 18854267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.